ClearPoint Neuro faces securities fraud probe after drug trial data disappoints, stock drops 23%.

Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following the release of disappointing clinical trial data by its partner, uniQure. The data showed the Huntington's disease treatment did not meet key clinical goals, causing ClearPoint's stock to plunge 23.12% on September 29, 2026. This investigation could lead to a class action lawsuit as investors seek to recover losses from the stock price decline. The law firm is encouraging affected investors to come forward.

ClearPoint Neuro currently has a market cap of $319.58 million and an enterprise value of $347.10 million on Pluang as of November 4, 2026, 06:01 WIB. The stock price is USD 9.67, down 2.81% in the last day, with a trading volume of 708,127 shares. Typical investors hold this stock for about 12 days on the platform, indicating relatively short-term trading activity following recent news events.